Valuation : Charles River Laboratories International, Inc.

Market Cap 14B 12.05B 11.31B 10.35B 19.31B 1,324B 19.46B 134B 52.09B 677B 52.59B 51.44B 2,179B P/E 2026 *
78.5x
P/E 2027 * 31.4x
Enterprise Value 16.12B 13.87B 13.01B 11.91B 22.22B 1,523B 22.4B 154B 59.95B 779B 60.52B 59.2B 2,507B EV / Sales 2026 *
4.12x
EV / Sales 2027 * 3.91x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Charles River Laboratories International, Inc.

1 day+0.82%
1 week-3.43%
Current month+0.96%
1 month+25.01%
1 week 231.36
Extreme 231.3635
233.98
1 month 210.07
Extreme 210.072
242.28
Current year 146.62
Extreme 146.619
242.28
1 year 146.62
Extreme 146.619
242.28
3 years 146.62
Extreme 146.619
242.28
5 years 146.62
Extreme 146.619
242.28
10 years 146.62
Extreme 146.619
242.28
Manager TitleAgeSince
Chief Executive Officer 56 2026-05-04
Director of Finance/CFO 58 2026-04-05
Chief Tech/Sci/R&D Officer 45 2026-01-11
Director TitleAgeSince
Chairman 75 1999-12-31
Director/Board Member 56 2026-05-04
Chairman 69 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%-3.43% - - 14B
-2.68%-2.57%-1.63%+14.84% 50.35B
-1.26%+0.36%+435.64%+519.26% 45.2B
-1.93%+1.68%+44.59%+20.49% 44.71B
-1.05%-2.19%+12.54%+75.11% 41.24B
+0.53%-1.67%+15.16%+49.88% 33.08B
-1.87%+7.43% - - 17.81B
-0.27%-1.05%+23.22%+124.19% 16.56B
-0.74%+0.77%+16.15%+28.34% 14.82B
-1.40%-0.68%+78.37%+41.72% 14B
Average -1.00%+0.01%+78.00%+109.23% 30.86B
Weighted average by Cap. -1.26%-0.46%+93.64%+126.72%

Financials

2026 *2027 *
Net sales 3.91B 3.37B 3.16B 2.89B 5.39B 370B 5.44B 37.36B 14.55B 189B 14.69B 14.37B 608B 4B 3.44B 3.23B 2.96B 5.52B 378B 5.56B 38.21B 14.88B 193B 15.02B 14.7B 622B
Net income 162M 140M 131M 120M 224M 15.35B 226M 1.55B 604M 7.84B 610M 596M 25.26B 428M 368M 345M 316M 590M 40.43B 594M 4.08B 1.59B 20.66B 1.61B 1.57B 66.54B
Net Debt 2.11B 1.82B 1.71B 1.56B 2.91B 200B 2.94B 20.17B 7.86B 102B 7.93B 7.76B 329B 1.63B 1.4B 1.32B 1.2B 2.25B 154B 2.27B 15.58B 6.07B 78.78B 6.12B 5.99B 254B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
26-09-03 CHF 233.98 +0.82%
26-09-02 CHF 232.08 +0.31%
26-09-01 CHF 231.36 -0.17%
26-08-31 CHF 231.75 -2.23%
26-08-28 CHF 237.04 -2.17%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
293.35USD
Average target price
281.00USD
Spread / Average Target
-4.21%

Quarterly revenue - Rate of surprise